US 11,980,652 B2
Compositions and methods for subcutaneous administration of cancer immunotherapy
Heather C. Losey, Lexington, MA (US); Jared Lopes, Wilmington, MA (US); Lei Sun, Waltham, MA (US); and Raymond J. Winquist, Marshfield, MA (US)
Assigned to Mural Oncology, Inc., Waltham, MA (US)
Filed by Mural Oncology, Inc., Waltham, MA (US)
Filed on Jan. 4, 2022, as Appl. No. 17/568,251.
Application 17/568,251 is a continuation of application No. 16/897,920, filed on Jun. 10, 2020, granted, now 11,246,906.
Claims priority of provisional application 62/932,160, filed on Nov. 7, 2019.
Claims priority of provisional application 62/924,356, filed on Oct. 22, 2019.
Claims priority of provisional application 62/860,182, filed on Jun. 11, 2019.
Prior Publication US 2022/0241370 A1, Aug. 4, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 38/16 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01)] 58 Claims
 
1. A method of treating cancer in a patient comprising periodically subcutaneously administering to the patient a dose of a fusion protein of SEQ ID NO: 1, or a fusion protein having a sequence identity of at least 80% over a contiguous sequence of at least about 20 amino acids up to the full length of SEQ ID NO: 1, wherein the periodic dosing is once every about 3 days to once every about 60 days.